CD80融合蛋白修饰的H22细胞激发抗肿瘤免疫  

H22 cells modified with CD80-IgG1Fc fusion protein elicit anti-tumor immune response of lymphocytes

作　　者：李和军[1] 李频[1] 郑祥雄[1] 周小玲[1] 

机构地区：[1]福建医科大学附属协和医院临床免疫研究所,福州350001

出　　处：《免疫学杂志》2007年第6期652-654,共3页Immunological Journal

基　　金：福建省科技厅基金资助项目(2003D06)

摘　　要：目的探讨CD80-IgG1 Fc段融合蛋白修饰的H22细胞对淋巴细胞抗肿瘤免疫的影响。方法应用福建省临床免疫研究所构建的CD80-IgG1 Fc段融合蛋白,修饰小鼠肝癌细胞株H22细胞,用流式细胞术检测修饰的H22细胞上CD80的表达。将修饰的H22细胞与小鼠脾细胞悬液混合后进行培养,分别应用MTT比色法、乳酸脱氢酶释放试验,检测经CD80-IgG1 Fc段融合蛋白修饰的H22细胞对脾淋巴细胞增殖及其细胞毒性的影响。结果CD80-IgG1 Fc段融合蛋白可有效地结合于H22细胞膜上(P<0.05),融合蛋白修饰的H22细胞可明显刺激脾淋巴细胞活化增殖并增强CTL的细胞毒活性(P<0.05)。结论CD80在抗肿瘤免疫中起着重要作用,用CD80-IgG1 Fc段融合蛋白修饰的H22细胞能明显增强淋巴细胞的特异性抗肿瘤免疫,为CD80用于肿瘤免疫治疗的研究提供了实验依据,为下一步体内免疫治疗肿瘤奠定了基础。Objective To investigate the anti-tumor immune response of lymphocytes elicited by H22 cells modified with CD80-IgG1 Fc fragment fusion protein （CD80-Fc）. Methods H22 cells were modified with CD80-Fc; the expression of CD80 on the surface of modified cell was analyzed by flow cytometry （FCM）. After mixed lymphocyte-tumour cell reaction （MLTR） of the modified H22 ceils and splenic lymphocytes of healthy mouse, the proliferation and cytotoxicity of the lymphocytes were tested by MTT colorimetry and LDH release assay, respectively. Results CD80-Fc could be efficiently bound on H22 cells. H22 cells modified with CD80-Fc fusion protein enhanced the proliferation and eytotoxicity of normal lymphocytes. Conclusion CD80 may play an important role in anti-tumour immune response. H22 cells modified with CD80-Fc fusion protein can elicit potent anti-tumor immune response. This fusion protein provides a foundation for immunotherapy of tumor in vivo.

关 键 词：CD80 融合蛋白 肿瘤免疫 

分 类 号：R730.5[医药卫生—肿瘤]